Cellectis S.A. (NASDAQ:CLLS – Get Rating) was the recipient of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 367,900 shares, a decline of 6.6% from the February 13th total of 393,800 shares. Based on an average trading volume of 150,100 shares, the short-interest ratio is currently 2.5 days.
Institutional Trading of Cellectis
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. OLD Mission Capital LLC bought a new stake in Cellectis in the fourth quarter valued at about $25,000. Millennium Management LLC increased its stake in Cellectis by 18.5% in the fourth quarter. Millennium Management LLC now owns 679,966 shares of the biotechnology company’s stock valued at $1,428,000 after acquiring an additional 106,125 shares during the period. Susquehanna International Group LLP bought a new stake in Cellectis in the fourth quarter valued at about $122,000. Envestnet Asset Management Inc. increased its stake in Cellectis by 26.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 57,447 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 11,928 shares during the period. Finally, Balyasny Asset Management LLC bought a new stake in Cellectis in the third quarter valued at about $42,000. Institutional investors own 22.61% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on CLLS shares. StockNews.com raised shares of Cellectis from a “sell” rating to a “hold” rating in a research report on Saturday, December 3rd. Citigroup cut their target price on shares of Cellectis from $36.00 to $24.00 in a research report on Wednesday, December 14th. Oppenheimer cut their price objective on shares of Cellectis from $16.00 to $13.00 and set an “outperform” rating for the company in a research report on Monday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $6.00 price objective on shares of Cellectis in a research report on Monday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.33.
Cellectis Stock Up 1.0 %
Shares of CLLS opened at $1.98 on Wednesday. The firm has a market capitalization of $110.05 million, a P/E ratio of -0.85 and a beta of 2.13. The company has a 50-day simple moving average of $2.68 and a 200-day simple moving average of $2.54. Cellectis has a 52 week low of $1.83 and a 52 week high of $5.04. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.65 and a current ratio of 2.28.
Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt’s proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals.